Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy targets tough-to-treat lymphoma

NCT ID NCT05996185

First seen Dec 12, 2025 · Last updated May 17, 2026 · Updated 17 times

Summary

This study tests whether adding the drug mogamulizumab to standard chemotherapy can improve outcomes for people with aggressive T-cell lymphoma. About 22 adults with newly diagnosed or returning lymphoma will receive the combination treatment. The main goal is to see how many patients achieve complete remission after six cycles.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T-CELL LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Icahn School of Medicine at Mount Sinai

    RECRUITING

    New York, New York, 10029, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Yale Cancer Center, Clinical Trials Office

    RECRUITING

    New Haven, Connecticut, 06510, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.